T Vesikari

Summary

Affiliation: University of Tampere
Country: Finland

Publications

  1. ncbi request reprint Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    N Engl J Med 354:23-33. 2006
  2. ncbi request reprint Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Vaccine 24:4821-9. 2006
  3. ncbi request reprint A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine
    Timo Vesikari
    University of Tampere, Tampere, Finland
    Pediatr Infect Dis J 25:590-5. 2006
  4. ncbi request reprint A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and
    Timo Vesikari
    Vaccine Research Center, University of Tampere, Finland
    Pediatr Infect Dis J 32:521-9. 2013
  5. pmc A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years
    Timo Vesikari
    Vaccine Research Center University of Tampere, Tampere, Finland
    Hum Vaccin Immunother 8:1882-91. 2012
  6. pmc Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
    Timo Vesikari
    Vaccine Research Center University of Tampere, Medical School FM3 Tampere, Finland
    Hum Vaccin Immunother 8:1892-903. 2012
  7. ncbi request reprint Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Lancet 381:825-35. 2013
  8. doi request reprint Rotavirus vaccination: a concise review
    T Vesikari
    University of Tampere, Vaccine Research Centre, Tampere, Finland
    Clin Microbiol Infect 18:57-63. 2012
  9. doi request reprint Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Hum Vaccin Immunother 8:921-8. 2012
  10. doi request reprint Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants
    Timo Vesikari
    Vaccine Research Center, Medical School, University of Tampere, Tampere, Finland
    Pediatr Infect Dis J 31:509-13. 2012

Detail Information

Publications78

  1. ncbi request reprint Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    N Engl J Med 354:23-33. 2006
    ..Rotavirus is a leading cause of childhood gastroenteritis and death worldwide...
  2. ncbi request reprint Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Vaccine 24:4821-9. 2006
    ....
  3. ncbi request reprint A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine
    Timo Vesikari
    University of Tampere, Tampere, Finland
    Pediatr Infect Dis J 25:590-5. 2006
    ..Previous studies with LAIV did not detect transmission to close contacts. The primary objective of this study was to estimate the probability of transmission to placebo contacts in a day care setting...
  4. ncbi request reprint A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and
    Timo Vesikari
    Vaccine Research Center, University of Tampere, Finland
    Pediatr Infect Dis J 32:521-9. 2013
    ....
  5. pmc A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years
    Timo Vesikari
    Vaccine Research Center University of Tampere, Tampere, Finland
    Hum Vaccin Immunother 8:1882-91. 2012
    ..MenACWY-TT induced higher functional antibody titers for all serogroups, which persisted longer for serogroups A, W-135 and Y, than the MenACWY polysaccharide vaccine...
  6. pmc Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
    Timo Vesikari
    Vaccine Research Center University of Tampere, Medical School FM3 Tampere, Finland
    Hum Vaccin Immunother 8:1892-903. 2012
    ..These results suggest that one single dose of MenACWY-TT induces a robust and persistent immune response and has an acceptable safety profile in toddlers...
  7. ncbi request reprint Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Lancet 381:825-35. 2013
    ..We assessed lot-to-lot consistency, safety and immunogenicity, and the effect of concomitant vaccination on responses to routine vaccines of an investigational multicomponent vaccine (4CMenB) in this population...
  8. doi request reprint Rotavirus vaccination: a concise review
    T Vesikari
    University of Tampere, Vaccine Research Centre, Tampere, Finland
    Clin Microbiol Infect 18:57-63. 2012
    ..The reasons for the slow progress in Europe include low mortality from RVGE, unfavourable cost-benefit calculations in some countries, and concerns that still exist over intussusception...
  9. doi request reprint Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Hum Vaccin Immunother 8:921-8. 2012
    ..Assessment of long-term antibody persistence after priming, and the effects of a one-year booster dose in children and adolescents was needed...
  10. doi request reprint Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants
    Timo Vesikari
    Vaccine Research Center, Medical School, University of Tampere, Tampere, Finland
    Pediatr Infect Dis J 31:509-13. 2012
    ..Potential impact of breast-feeding on the efficacy and immunogenicity of human rotavirus G1P[8] vaccine was examined in this exploratory analysis...
  11. doi request reprint Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Vaccine 30:3082-9. 2012
    ..Dose 1 may be administered at 9 months if early protection is required, but it should be recognised that a second dose is required promptly with a minimum of 3-month interval between doses...
  12. doi request reprint Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    Vaccine 30:1388-96. 2012
    ....
  13. doi request reprint Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Int J Infect Dis 11:S29-35. 2007
    ....
  14. doi request reprint MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination
    T Vesikari
    University of Tampere Medical School, Medical School FM3, 33014 Tampere, Finland
    Vaccine 27:6291-5. 2009
    ..Altogether, these data further support the potential use of MF59-adjuvanted influenza vaccine as a safe and highly immunogenic influenza vaccine for young children...
  15. doi request reprint Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 28:563-71. 2009
    ..Adjuvanted influenza vaccines may offer a solution...
  16. ncbi request reprint Rotavirus vaccines
    Timo Vesikari
    University of Tampere, Medical School, Vaccine Research Center, Finland
    Scand J Infect Dis 40:691-5. 2008
    ..Both vaccines have now been distributed in millions of doses. Post-marketing data have not shown any gross signal for IS with either vaccine, but further data and analyses are required for final conclusion on safety of these vaccines...
  17. ncbi request reprint Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study
    T Vesikari
    Vaccine Research Centre, Medical School, University of Tampere, Tampere, Finland
    Lancet 370:1757-63. 2007
    ..We aimed to assess the efficacy of the oral live attenuated human rotavirus vaccine Rotarix (RIX4414) for prevention of rotavirus gastroenteritis in European infants during their first 2 years of life...
  18. doi request reprint Emerging data on the safety and efficacy of influenza vaccines in children
    Timo Vesikari
    University of Tampere Medical School Vaccine Research Center, University of Tampere, Tampere, Finland
    Pediatr Infect Dis J 27:S159-61. 2008
    ..This article will focus mainly on the efficacy of live attenuated intranasal influenza vaccine as an option in young children...
  19. doi request reprint European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    J Pediatr Gastroenterol Nutr 46:615-8. 2008
  20. doi request reprint European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    J Pediatr Gastroenterol Nutr 46:S38-48. 2008
  21. doi request reprint Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Pediatrics 121:e568-73. 2008
    ....
  22. doi request reprint An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adol
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 29:314-8. 2010
    ..In this study, we evaluated the immunogenicity and safety of GARDASIL administered concomitantly with REPEVAX (diphtheria, tetanus, acellular pertussis, and poliomyelitis vaccine)...
  23. doi request reprint Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 29:957-63. 2010
    ..This study evaluated whether RV5 remained efficacious beyond 2 years...
  24. doi request reprint Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial
    Timo Vesikari
    Vaccine Research Center, University of Tampere, Biokatu 10, Tampere, Finland
    J Clin Virol 53:22-8. 2012
    ..Conventional techniques for diagnosing influenza based on viral cell culture or disease serology have limitations, and molecular assays, such as real-time polymerase chain reaction (rtPCR) are increasingly used...
  25. doi request reprint Oil-in-water emulsion adjuvant with influenza vaccine in young children
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    N Engl J Med 365:1406-16. 2011
    ..The efficacy of inactivated influenza vaccines is known to be poor in infants and young children...
  26. doi request reprint Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 30:e130-41. 2011
    ..We evaluated catch-up vaccination schedules with 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)...
  27. doi request reprint Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Vaccine 29:4274-84. 2011
    ..ACWY-TT can be co-administered with MMRV without affecting immunogenicity or safety profiles of either vaccine. This study has been registered at www.clinicaltrials.gov NCT00474266...
  28. doi request reprint Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants
    T Vesikari
    Vaccine Research Center, Medical School, University of Tampere, FIN 33014 Tampere, Finland
    Vaccine 29:2079-84. 2011
    ..1-90.8%) and 90.5% (95% CI: 86.2-93.8%). Reactogenicity and safety profiles of the two vaccine formulations were similar. Liquid formulation of the rotavirus vaccine allows greater flexibility in supply and reduces logistical costs...
  29. doi request reprint Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence
    Timo Vesikari
    University of Tampere, School of Medicine, Vaccine Research Center, FM3, Biokatu 10, 33520 Tampere, Finland
    Pediatrics 126:e762-70. 2010
    ..This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population 6 months through 17 years of age...
  30. pmc Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Biokatu 10, Tampere, Finland
    Eur J Pediatr 169:1379-86. 2010
    ....
  31. doi request reprint Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe
    Timo Vesikari
    University of Tampere, Medical School, FIN 33014 Tampere, Finland
    Vaccine 28:5272-9. 2010
    ..RIX4414 was immunogenic and well tolerated in European infants and the co-administration of routine childhood vaccines with RIX4414 did not negatively impact the immune responses to these vaccines...
  32. doi request reprint Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 29:e47-56. 2010
    ..This study examined the safety, reactogenicity, and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with MMRV vaccine...
  33. ncbi request reprint Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 26:632-8. 2007
    ....
  34. doi request reprint RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Vaccine 28:345-51. 2009
    ..5% (95% CI, 91.3-96.8%) for up to 2 years after vaccination. There were no statistically significant differences between RotaTeq and placebo for any of the safety outcomes. In Europe, RotaTeq was highly efficacious and well tolerated...
  35. ncbi request reprint Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 26:153-8. 2007
    ..Given the overlap in MMR and varicella vaccination schedules, development of a combined vaccine appears logical and would facilitate the introduction of 2 doses of varicella vaccination in healthy children with no additional injections...
  36. ncbi request reprint Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, FIN 33014 Tampere, Finland
    Pediatr Infect Dis J 23:937-43. 2004
    ..Rotavirus gastroenteritis, a major cause of mortality and morbidity worldwide, is a vaccine-preventable disease. New safe and effective candidate rotavirus vaccines are needed to replace the withdrawn rhesus rotavirus-based oral vaccine...
  37. ncbi request reprint Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants
    T Vesikari
    Medical School FM3, University of Tampere, 33014, Finland
    Vaccine 22:2836-42. 2004
    ..It is concluded that RIX4414 strain HRV vaccine is virtually non-reactogenic and, at high titer, highly immunogenic in susceptible infants...
  38. ncbi request reprint Clinical trials of rotavirus vaccines in Europe
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 25:S42-7. 2006
    ..A large scale safety trial, conducted in Latin America plus Finland, indicated no increased risk of intussusception among recipients of Rotarix compared with placebo. The licensure of Rotarix is in process in the European Union...
  39. ncbi request reprint Neonatal administration of rhesus rotavirus tetravalent vaccine
    Timo Vesikari
    University of Tampere Medical School, Biokatu 10, 33520 Tampere, Finland
    Pediatr Infect Dis J 25:118-22. 2006
    ..We hypothesized that giving the first dose of RRV-TV vaccine during the neonatal period might reduce the reactogenicity of RRV-TV vaccine without compromising the utilization of the vaccine...
  40. ncbi request reprint A short report on highlights of world-wide development of RIX4414: an European experience
    T Vesikari
    University of Tampere, Medical School FM3, Vaccine Research Center, University of Tampere, 33014 Tampere, Finland
    Vaccine 24:3779. 2006
  41. ncbi request reprint [Varicella vaccinations for everybody or for selected groups?]
    Timo Vesikari
    Tampereen yliopiston lääketieteen laitos FM3 33014 Tampereen yliopisto
    Duodecim 118:81-5. 2002
  42. ncbi request reprint Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care
    Timo Vesikari
    Tampere University Medical School FM3, Biokatu 10, 33520 Tampere, Finland
    Pediatrics 118:2298-312. 2006
    ....
  43. ncbi request reprint Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    J Infect Dis 194:370-6. 2006
    ..A corresponding tetravalent (types G1, G2, G3, and G4) reassortant vaccine based on bovine-human (UK) rotavirus reassortant tetravalent (BRV-TV) vaccine was developed concurrently...
  44. pmc Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007
    L Puustinen
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Epidemiol Infect 140:268-75. 2012
    ..b was dominant between 2003 and 2004 (83%). In conclusion, genotypes GII.4 and GIIb have emerged as predominant norovirus genotypes in endemic gastroenteritis affecting young infants and children in Finland...
  45. ncbi request reprint Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis
    X L Pang
    Department of Virology, University of Tampere Medical School, Finland
    J Clin Virol 13:9-16. 1999
    ..A sensitive method, like reverse transcription polymerase chain reaction (RT-PCR), may reveal more rotaviruses, but the clinical significance of such findings is not well established...
  46. ncbi request reprint Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines
    T Vesikari
    University of Tampere Medical School, Finland
    Acta Paediatr 88:513-20. 1999
    ..However, febrile reactions to RRV-TV rotavirus vaccine are common when the first dose is given at the age of 3 mo...
  47. ncbi request reprint Effect of rotavirus vaccine on Sapporo virus gastroenteritis in Finnish infants
    X L Pang
    Department of Virology, University of Tampere, Medical School, Finland
    Pediatr Infect Dis J 20:295-300. 2001
    ..SLV disease is characterized by diarrhea, which is usually mild but can be severe. By an unknown mechanism rotavirus vaccine seems to reduce the severity of SLV-associated diarrhea...
  48. ncbi request reprint Human caliciviruses in acute gastroenteritis of young children in the community
    X L Pang
    Department of Virology and Pediatrics, University of Tampere Medical School, Tampere, Finland
    J Infect Dis 181:S288-94. 2000
    ..As a group, human caliciviruses are common causative agents of gastroenteritis in children <2 years of age in Finland, and, of these, NLVs cause more severe disease than SLVs...
  49. doi request reprint One-step quantitative RT-PCR for the detection of rotavirus in acute gastroenteritis
    S Q Zeng
    Vaccine Research Center, University of Tampere, Medical School, Vaccine Research Center, Biokatu 10, FIN 33520 Tampere, Finland
    J Virol Methods 153:238-40. 2008
    ..e. 28% more rotavirus positive cases than identified by EIA. It is concluded that Q-PCR using primers targeted at NSP3 is a rapid and sensitive method for diagnosing acute rotavirus gastroenteritis...
  50. doi request reprint Aichi virus infection in children with acute gastroenteritis in Finland
    S Kaikkonen
    Vaccine Research Centre, University of Tampere Medical School, Biokatu 10, Tampere, Finland
    Epidemiol Infect 138:1166-71. 2010
    ..5%), of which four were co-infections with other gastroenteritis viruses. Two Aichi virus genotypes, A and B, were found. Aichi virus appears to be rare in children with acute gastroenteritis in Finland...
  51. ncbi request reprint Rotavirus vaccines: development and use for the prevention of diarrhoeal disease
    T Vesikari
    University of Tampere, School of Medicine, Finland
    Ann Med 31:79-85. 1999
    ..Protective efficacy of RRV-TV vaccine in developing countries is lower and a more intensive immunization schedule may be needed. Several other candidate rotavirus vaccines, including bovine-human reassortants, are being investigated...
  52. doi request reprint Mixed viral infections causing acute gastroenteritis in children in a waterborne outbreak
    S Räsänen
    University of Tampere Medical School, Tampere, Finland
    Epidemiol Infect 138:1227-34. 2010
    ..Bloody diarrhoea occurred only when C. jejuni was present. To conclude, massive exposure to several AGE viruses caused mixed infections and severe AGE regardless of the aetiological agents...
  53. doi request reprint Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography
    L Huhti
    Vaccine Research Center, University of Tampere Medical School, Biokatu 10, 33520 Tampere, Finland
    Arch Virol 158:933-42. 2013
    ..Here, we describe a method for NoV VLP purification and several methods for determining their purity, including quantitative PCR for BV DNA detection...
  54. doi request reprint Prevalence of norovirus GII-4 antibodies in Finnish children
    K Nurminen
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    J Med Virol 83:525-31. 2011
    ..Therefore, protection against NoV infection correlated with strong blocking activity...
  55. doi request reprint Foreword: ESPID/ESPGHAN evidence-based recommendations for rotavirus vaccination in Europe
    Timo Vesikari
    Tampere, Finland
    J Pediatr Gastroenterol Nutr 46:v-vi. 2008
  56. ncbi request reprint Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation
    H Viskari
    JDRF Center for Prevention of Type 1 Diabetes in Finland, Finland
    Diabetologia 48:1280-7. 2005
    ....
  57. pmc A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles
    L Huhti
    Vaccine Research Center, University of Tampere Medical School, Finland
    Arch Virol 155:1855-8. 2010
    ..VLPs were stable for at least 12 months at 4°C, and up to 7 days at ambient temperature. These findings indicate that this method yielded stable and high-quality VLPs...
  58. ncbi request reprint A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies
    Kai Krohn
    Institute of Medical Technology, University of Tampere, Biokatu 8, 33520 Tampere, Finland
    Microbes Infect 7:1405-13. 2005
    ....
  59. doi request reprint Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 28:S66-76. 2009
    ..The immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed and compared with the 7-valent pneumococcal conjugate vaccine (7vCRM)...
  60. doi request reprint Detection of human coronaviruses in children with acute gastroenteritis
    Minna Risku
    Department of Virology, Medical School, Biokatu 10, FI 33014 University of Tampere, Tampere, Finland
    J Clin Virol 48:27-30. 2010
    ..Human coronaviruses (HCoVs) are known respiratory pathogens. Moreover, coronavirus-like particles have been seen by electron microscope in stools, and SARS-HCoV has been isolated from intestinal tissue and detected in stool samples...
  61. ncbi request reprint Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial
    Péter Csonka
    Department of Pharmacy, University of Tampere School of Public Health and Research Unit, and the Tampere University Hospital, Tampere, Finland
    J Pediatr 143:725-30. 2003
    ..Study design Randomized, double-blind, placebo-controlled trial involving 230 children age 6 to 35 months in the emergency department. Each patient received either oral prednisolone (2 mg/kg/d) or placebo for 3 days...
  62. doi request reprint Rotavirus gastroenteritis in Finnish children in 2006-2008, at the introduction of rotavirus vaccination
    Sirpa Räsänen
    University of Tampere Medical School, Tampere, Finland
    Scand J Infect Dis 43:58-63. 2011
    ..RV-associated hospitalizations were seen in children up to the age of 9 y. This study forms the epidemiological background for the follow-up of the impact of universal RV vaccination in Finland introduced in 2009...
  63. doi request reprint Norovirus gastroenteritis in young children receiving human rotavirus vaccine
    Shang Qin Zeng
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    Scand J Infect Dis 42:540-4. 2010
    ..NVs were the most common etiologic agents of AGE in children under 2 y of age. Human rotavirus vaccine did not protect against NV gastroenteritis...
  64. doi request reprint IL-10 gene polymorphism at -1082 A/G is associated with severe rhinovirus bronchiolitis in infants
    Merja Helminen
    Paediatric Research Centre, Tampere University and University Hospital, Tampere, Finland
    Pediatr Pulmonol 43:391-5. 2008
    ..This finding suggests a different pathogenic mechanism for RSV bronchiolitis as compared with wheezing associated with other viral infections, for example, rhinovirus in infants under 6 months of age...
  65. ncbi request reprint Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life
    Stan L Block
    Kentucky Pediatric Adult Research, Bardstown, Kentucky, USA
    Pediatrics 119:11-8. 2007
    ..Rotavirus is the leading cause of dehydrating acute gastroenteritis in infants worldwide. Previous studies of a live pentavalent human-bovine reassortant rotavirus vaccine have shown it to be efficacious across a range of potencies...
  66. ncbi request reprint Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres
    Clare L Hibbert
    RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, United Kingdom
    Vaccine 25:8010-20. 2007
    ..2%; placebo, 13.4%), vaccination saved US$ 5.47 per child in societal costs. In the high attack-rate season (vaccinated, 4.7%; placebo, 32.1%), vaccination led to a societal costs savings of US$ 144.44 per child...
  67. doi request reprint Rotavirus
    Jim Gray
    Centre for Infections, Health Protection Agency, London, UK
    J Pediatr Gastroenterol Nutr 46:S24-31. 2008
  68. ncbi request reprint Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis
    Guillermo M Ruiz-Palacios
    Instituto Nacional de Ciencas Medicas y Nutricion, Mexico Distrito Federal, Mexico
    N Engl J Med 354:11-22. 2006
    ..The safety and efficacy of an attenuated G1P[8] human rotavirus (HRV) vaccine were tested in a randomized, double-blind, phase 3 trial...
  69. ncbi request reprint Burden of rotavirus disease in European Union countries
    Montse Soriano-Gabarro
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Pediatr Infect Dis J 25:S7-S11. 2006
    ..With the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine-preventable disease among children in the EU...
  70. ncbi request reprint A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception
    Albert Z Kapikian
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 192:S22-9. 2005
    ..e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination...
  71. ncbi request reprint A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis
    Beatrice De Vos
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Pediatr Infect Dis J 23:S179-82. 2004
    ..05) in Latin America. These results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation...
  72. ncbi request reprint Viral etiology and incidence of acute gastroenteritis in young children attending day-care centers
    Vibeke Rosenfeldt
    University Clinic of Pediatrics, H S Hvidovre Hospital, Hvidovre, Denmark
    Pediatr Infect Dis J 24:962-5. 2005
    ..The purpose of the study was to investigate the frequency, morbidity and cause of acute gastroenteritis in children attending day-care centers in Denmark...
  73. ncbi request reprint Rotavirus types in Europe and their significance for vaccination
    Ulrich Desselberger
    Cambridge, United Kingdom
    Pediatr Infect Dis J 25:S30-41. 2006
    ..A case is made for comprehensive surveillance of cocirculating human rotavirus types in Europe after the implementation of rotavirus vaccination...
  74. ncbi request reprint Live attenuated versus inactivated influenza vaccine in infants and young children
    Robert B Belshe
    Saint Louis University Health Sciences Center, St Louis, USA
    N Engl J Med 356:685-96. 2007
    ..S. advisory bodies. To evaluate alternative vaccine approaches, we compared the safety and efficacy of intranasally administered live attenuated influenza vaccine with those of inactivated vaccine in infants and young children...
  75. doi request reprint Options for the prevention of rotavirus disease other than vaccination
    Jacek Mrukowicz
    Polish Institute for Evidence Based Medicine, Krakow, Poland
    J Pediatr Gastroenterol Nutr 46:S32-7. 2008
  76. ncbi request reprint JC virus strains indigenous to northeastern Siberians and Canadian Inuits are unique but evolutionally related to those distributed throughout Europe and Mediterranean areas
    Chie Sugimoto
    Laboratory of Viral Infection, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4 6 1 Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    J Mol Evol 55:322-35. 2002
    ..Based on the present findings, we discuss ancient human migrations, accompanied by Type A JCVs, across Asia and to Arctic areas of North America...
  77. ncbi request reprint A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland
    Anita Kondrashova
    Juvenile Diabetes Research Foundation, Center for Prevention of Type 1 Diabetes, Finland
    Ann Med 37:67-72. 2005
    ..We assessed the contribution of environmental and genetic factors to type 1 diabetes by comparing the incidence in two neighboring populations living in conspicuously different socioeconomic circumstances...
  78. ncbi request reprint Genetic diversity of JC virus in the Saami and the Finns: implications for their population history
    Hiroshi Ikegaya
    Department of Forensic Medicine, University of Turku, Turku, Finland 20520
    Am J Phys Anthropol 128:185-93. 2005
    ..These findings are discussed in the context of the population history of the Saami and the Finns. This study provides new complete JCV DNA sequences derived from populations of anthropological interest...